Tekla Life Sciences Investors vs ASML Holding NV
A head-to-head of Tekla Life Sciences Investors (HQL) and ASML Holding NV (ASMLF) across valuation, profitability, growth, and dividends. Green marks the more favourable value on that metric only — not a recommendation.
| Metric | HQL | ASMLF |
|---|---|---|
| Market Cap | $553.12M | $541.44B |
| P/E (TTM) | 3.07 | 44.97 |
| Forward P/E | 0.00 | 40.16 |
| P/S | 285.35 | 16.07 |
| P/B | 1.02 | 22.44 |
| EV/EBITDA | 0.00 | 38.65 |
| Dividend Yield | 10.14% | 0.55% |
| Profit Margin | 505.41% | 30.86% |
| Gross Margin | 100.00% | 52.83% |
| Operating Margin | 99.08% | 34.60% |
| Revenue Growth (YoY) | +463.30% | +13.25% |
| FCF Yield | — | 1.65% |
| Debt / Equity | — | 12.99 |
| Current Ratio | 1.74 | 1.36 |
Share:
Compare Tekla Life Sciences Investors with others
This comparison is for informational and educational purposes only, based on available data — not a recommendation to buy or sell any stock.